EUVIMEDEUVIMED entdecken
Crossref

Trends in thyroid Bethesda category III in the era of molecular testing: a single-center study

Aleksander Luniewski, Nouran Sinada, Kristen Atkins, Edward Stelow, Eyas Alzayadneh

Journal of the American Society of Cytopathology · 2026-06

DOI: 10.1016/j.jasc.2026.06.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society of Cytopathology, 2026-06. Verfasst von Aleksander Luniewski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Virginia, Charlottesville, Virginia. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Molecular testing is increasingly integrated into the management of indeterminate thyroid fine-needle aspiration (FNA) diagnoses, particularly The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) category III. However, it remains unclear how increasing test availability has affected cytopathologists' use of this category and whether its expansion risks incorporating nodules that may not warrant surgery, particularly following the 2023 TBSRTC nomenclature updates. MATERIALS AND METHODS We retrospectively queried all in-house thyroid FNAs from 2018 to 2024, assessing temporal trends in TBSRTC category distribution, with focused analysis of TBSRTC III cases and associated parameters including ThyroSeq utilization, atypia of undetermined significance:malignant ratio, and risk of malignancy (ROM). RESULTS From 2018 to 2024, TBSRTC III interpretations increased significantly (6%-26% of FNAs), accompanied by increased ThyroSeq utilization in this category (5%-75%) and atypia of undetermined significance:malignant ratios (1.0-4.5). Meanwhile, the proportion of TBSRTC III cases undergoing surgery declined (40%-26%). Surgical selection became strongly influenced by molecular results, with 71% of ThyroSeq-positive TBSRTC III nodules undergoing resection in 2024 compared with only 3% of ThyroSeq-negative nodules. Increased use of TBSRTC III occurred primarily at the expense of category II, while categories IV-VI remained stable. ROM was not statistically different with and without molecular testing. Molecular changes were consistent with published ThyroSeq cohorts. CONCLUSIONS These findings suggest that increased ThyroSeq utilization is associated with increased use of TBSRTC III and more selective surgical management without altering ROM or increasing the inclusion of lesions less likely to require surgery.

Schlagwörter

Stichwörter der Autor:innen

Atypia of undetermined significance/follicular lesion of undetermined significa…The Bethesda System for Reporting Thyroid CytopathologyThyroSeqThyroid cytologyThyroidectomy

Autor:innen und Institutionen

  • Department of Pathology, University of Virginia, Charlottesville, Virginia.
  • Department of Pathology, University of Virginia, Charlottesville, Virginia. Electronic address: hbj7gu@uvahealth.org.

Zitieren

APA

Luniewski, A., Sinada, N., Atkins, K., Stelow, E., & Alzayadneh, E. (2026). Trends in thyroid Bethesda category III in the era of molecular testing: a single-center study. Journal of the American Society of Cytopathology. https://doi.org/10.1016/j.jasc.2026.06.002

Vancouver

Luniewski A, Sinada N, Atkins K, Stelow E, Alzayadneh E. Trends in thyroid Bethesda category III in the era of molecular testing: a single-center study. Journal of the American Society of Cytopathology. 2026. doi:10.1016/j.jasc.2026.06.002

BibTeX
@article{Luniewski2026,
  author = {Luniewski, Aleksander and Sinada, Nouran and Atkins, Kristen and Stelow, Edward and Alzayadneh, Eyas},
  title = {Trends in thyroid Bethesda category III in the era of molecular testing: a single-center study},
  journal = {Journal of the American Society of Cytopathology},
  year = {2026},
  doi = {10.1016/j.jasc.2026.06.002}
}
Kostenlos starten →